A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects
Status:
Completed
Trial end date:
2017-10-16
Target enrollment:
Participant gender:
Summary
This is a Thorough QT study intended to estimate the effect of glasdegib at therapeutic
exposure and at supra-therapeutic exposure on cardiac repolarization in healthy subjects.
This is a randomized, double blind, positive and placebo controlled study with a 6 day
washout between successive periods.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination